PWPS
CTKB icon

Pinnacle Wealth Planning Services’s Cytek Biosciences CTKB Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,313
Closed -$18.8K – 2766
2026
Q1 		$18.8K Buy
4,313
+825
+24% +$3.9K ﹤0.01% 1718
2025
Q4 		$17.6K Buy
+3,488
New +$16.2K ﹤0.01% 1778

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Pinnacle Wealth Planning Services's CTKB Position: Q2 2026 in Review

Pinnacle Wealth Planning Services sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 4,313 shares — an estimated $18.8K sold.

Pinnacle Wealth Planning Services first reported a position in CTKB in Q4 2025 and held it in 2 quarters. The position peaked at $18.8K in Q1 2026. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Pinnacle Wealth Planning Services reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
  • Pinnacle Wealth Planning Services sold 4,313 Cytek Biosciences shares in Q2 2026, an estimated $18.8K.
  • Pinnacle Wealth Planning Services first reported a position in Cytek Biosciences in Q4 2025 and held it in 2 quarters.
  • Pinnacle Wealth Planning Services's Cytek Biosciences position peaked at $18.8K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q2 2026, filed 7 Aug 2026.